Stage D前立腺癌に対するCyclophoshamide大量間歇療法

Abstract

Cyclophosphamide (Endoxan) 700-1000mg was administered by drip infusion on an outpatient basis, at an interval of 3-4weeks to 13 patients confirmed to have clinical stage D prostatic cancer. All of the cancers were progressing and had failed to respond to endocrine therapy or were relapse cases. The following results were obtained. According to Karnofsky's efficacy evaluation standards, 1 case was 1-B, 4 cases were 1-A, 1 case was 0-B, 2 cases were 0-A, and 5 cases were 0-0. Five cases (38.5%) showed objective responses, and 3 cases showed subjective responses. According to NPCP efficacy evaluation standards, there was partial regression in 1 case and progression in 5 cases; and, 7 cases were stable. The effective rate was 61.5% (8 out of 13), when stable or better was judged as effective. As to the principal toxicity of Endoxan, reduction of WBC to 3000-4000/mm3 was noted in 5 cases, and gastrointestinal symptoms were seen in 11 cases. But these were mild; and, no treatment was considered necessary.